Inventor · disambiguated record
Tracy Chia-Chien Kuo
Also filed as: KUO TRACY CHIA-CHIEN
20 granted patents·9 pending applications·152 citations·filing 2016–2024
95Inventor score
Top patents by PatentIndex Score
29 records- 0197US11208459B2Constructs having a SIRP-alpha domain or variant thereofALX ONCOLOGY INC·Filed 2020·Granted Dec 28, 2021·8 cites·54 claims
- 0296US11814435B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Nov 14, 2023·5 cites·7 claims
- 0396US10696730B2Constructs having a SIRP-alpha domain or variant thereofALX ONCOLOGY INC·Filed 2018·Granted Jun 30, 2020·11 cites·54 claims
- 0496US10259859B2Constructs having a SIRP-α domain or variant thereofALX ONCOLOGY INC·Filed 2016·Granted Apr 16, 2019·35 cites·137 claims
- 0596US9969809B2Therapeutic antibodies and their usesPFIZER·Filed 2016·Granted May 15, 2018·44 cites·8 claims
- 0695US11155630B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Oct 26, 2021·3 cites·14 claims
- 0794US11242404B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2021·Granted Feb 8, 2022·3 cites·30 claims
- 0893US11639376B2Constructs having a SIRP-α domain or variant thereofALX ONCOLOGY INC·Filed 2020·Granted May 2, 2023·3 cites·28 claims
- 0992US12098214B2Combination therapies for treating cancerALX ONCOLOGY INC·Filed 2022·Granted Sep 24, 2024·2 cites·6 claims
- 1092US10294304B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2016·Granted May 21, 2019·16 cites·22 claims
- 1191US11939393B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2022·Granted Mar 26, 2024·1 cites·24 claims
- 1291US11401338B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2017·Granted Aug 2, 2022·6 cites·37 claims
- 1391US10793635B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 1489US11795463B2Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·16 claims
- 1589US10040860B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Aug 7, 2018·6 cites·8 claims
- 1685US11920136B2Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2021·Granted Mar 5, 2024·1 cites·47 claims
- 1785US2024018252A1Therapeutic antibodies and their usesPFIZER·Filed 2023·Application pending·0 cites
- 1885US2024343778A1Constructs having a sirp-alpha domain or variant thereofALX ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1984US11292850B2Antibodies against signal-regulatory protein α and methods of useALX ONCOLOGY INC·Filed 2019·Granted Apr 5, 2022·2 cites·62 claims
- 2082US11312782B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2019·Granted Apr 26, 2022·1 cites·46 claims
- 2179US2024191242A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2278US2024287528A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2375US12404340B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2021·Granted Sep 2, 2025·0 cites·37 claims
- 2475US2024075101A1Combination therapies for treating cancerALX ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2573US11912776B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 2664US2024382610A1Nectin-4 antibodies and conjugatesTALLAC THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2764US2021154269A1Combination therapies for treating cancerALX ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2861US2024374746A1Sirp-alpha antibodies and conjugatesTALLAC THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2948US2022096649A1Immunomodulating polynucleotide conjugates and methods of useTALLAC THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tracy Chia-Chien Kuo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →